En Es
Categories

Industry News


Bioperfectus Partners with FIND to Increase COVID-19 Self-Testing Capacity in Low and Middle-Income Countries

By Labmedica International staff writers
15 Mar 2022

Image: Bioperfectus has partnered with FIND to lift COVID-19 self-testing capacity in LMICs (Photo courtesy of Bioperfectus)

Jiangsu Bioperfectus Technologies Co., Ltd. (Shanghai, China), a leading in-vitro diagnostics provider for infectious diseases, has partnered with FIND (Geneva, Switzerland), the global alliance for diagnostics, to accelerate the availability of affordable SARS-CoV-2 self-tests in low- and middle-income countries (LMICs).


Bioperfectus is pioneering in the molecular diagnostics market with products ranging from real-time PCR kits, nucleic acid extraction systems, rapid tests and automation laboratory devices. FIND, the global alliance for diagnostics, seeks to ensure equitable access to reliable diagnosis worldwide. FIND connects countries and communities, funders, decision-makers, healthcare providers and developers to spur diagnostic innovation and make testing an integral part of sustainable, resilient health systems. FIND is co-convener of the Access to COVID-19 Tools (ACT) Accelerator diagnostics pillar and a WHO Collaborating Centre for Laboratory Strengthening and Diagnostic Technology Evaluation.


FIND had launched request for proposal (RFP) in March 2021 in the context of the ACT Accelerator diagnostics pillar, which includes strengthening capacity for countries to expand access to COVID-19 testing based on strategies to reach people where they live, work, and seek care, such as community-based testing and self-testing. In response to the open call, Bioperfectus joined the communication and collaboration, with its fast reaction to the COVID-19 pandemic, advanced R&D capacity, affordability and unique design of its ONE-STEP” COVID-19 Self-testing product. Bioperfectus was chosen from over 80 applicants for fulfilling all the criteria, including the test’s technical performance, suitability for self-administration, and affordability for LMICs. The investment is funded by the German Federal Ministry of Education and Research through KfW and other donors through grants to FIND. FIND will supplement this financial investment with technical support and conduct an independent evaluation of the performance and usability of the tests in the settings of intended use. All help is dependent on a series of mutually agreed project milestones being successfully met.


“We Bioperfectus are very honored to cooperate with FIND to offer bioPerfectus COVID-19 Ag Self-test Kit to LMICs and bridge the gap between the LMICs and HICs (High-income countries) in COVID-19 Self-testing,” the company said in a statement.


Related Links:
Jiangsu Bioperfectus Technologies Co., Ltd. 
FIND 



E-mail Print
FaceBook Twitter Google+ Linked in

BioPerfectus Technologies

Bioperfectus Technologies Co., Ltd. is one of the leading molecular diagnostic solution providers in the global in-vitro diagnostic market since 2010. The company’s products ranging from real time PCR kits, nucleic acid extraction systems, rapid tests, automation laboratory devices, etc., are distributed in over 50 countries across the world.
Gold member
More info

Additional news

27 Jun 2022
Robot-Assisted Surgical Devices Market Driven by Increased Demand for Patient-Specific Surgeries
Given the growing incidence of lifestyle diseases and demand for affordable healthcare, effective surgery using robotic devices can result in a decline in treatment costs and drive the growth of the global robot-assisted surgical devices (RASD) market.
Read More
24 Jun 2022
Fujirebio Acquires ADx NeuroSciences to Speed Development of Neurodegenerative Diseases Diagnostic Tests
Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction of customary closing conditions.
Read More
23 Jun 2022
Hospital Microbiology Testing Market Driven by Increasing Prevalence of Chronic Diseases
Rising medical expenditure as well as the presence of well-established modern healthcare infrastructure in various developed as well as developing regions is fueling the growth of the global hospital microbiology testing market.
Read More
22 Jun 2022
Global Minimally Invasive Surgery (MIS) Market to Surpass USD 325 Billion by 2031
The global MIS market is projected to surpass USD 325 billion by 2031, driven by growing patient awareness of the advantages of MIS over open surgeries, continuous innovation in surgical robots, and constant advancements in other MIS-associated technologies during the 2022-2031 forecast period.
Read More
21 Jun 2022
Medix Biochemica Acquires IVD Raw Materials Producer Bioresource Technology
Medix Biochemica (Espoo, Finland) has acquired 100% of the shares of Bioresource Technology (BRT, Weston, FL, USA) to broaden its base matrix capabilities and further strengthen its local presence in the US market.
Read More
21 Jun 2022
Global Bedside Testing Market to Witness Promising Prospects in Critical Care
Point-of-care or point-of-use diagnostics, also known as bedside testing, has gained increased prominence in analytical testing over the past few years as it provides clinically relevant information without the need for a dedicated laboratory.
Read More
20 Jun 2022
Global Sepsis Diagnostics Market Driven by Rising Hospital-Acquired Illnesses
The global sepsis diagnostics market is expected to grow at a CAGR of 8.3% during the period 2022-2028 to reach almost USD 0.88 billion by 2028, driven by a rise in the number of hospital-acquired illnesses and the rapidly growing molecular diagnostics market, although the high cost of automated diagnostic instruments could hamper market growth.
Read More
14 Jun 2022
BD Partners with Mayo Clinic Platform for Access to World's Largest Collection of Clinical Data
Becton, Dickinson and Company (BD, Franklin Lakes, NJ, USA) has entered into a collaboration with Mayo Clinic Platform (Rochester, MN, USA) to access de-identified patient data from Mayo Clinic Platform_Discover.
Read More
14 Jun 2022
Quidel Partners with Global Lyme Alliance, Leads in Lyme Disease Testing
Quidel Corporation (San Diego, CA, USA) is joining forces with Global Lyme Alliance (Stamford, CT, USA) to heighten public awareness around Lyme disease during Lyme Disease Awareness Month (in May) and beyond.
Read More
Copyright © 2000-2022 TradeMed.com. All rights reserved. | Terms And Conditions